Patent · US Active

Drug combination containing TLR7 agonist

US12336996B2 · kind B2 · utility

0Cited by

0References

19Claims

0Family size

Assignee

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · CN

Inventors

Hongjiang Xu · Lianyungang, CN
Dandan Lu · Lianyungang, CN
Xingfeng Ge · Nanjing, CN
Wei Song · Houston, US
Wei Shi · 安丰镇, CN
Ling Yang · Lianyungang, CN
Xiquan Zhang · 安丰镇, CN
Hao Yu · Hefei, CN
Zhongnan Xu · Lianyungang, CN

Key dates

Filing date	Sep 29, 2020
Grant date	Jun 24, 2025
Priority date	—
Expiry date	Oct 15, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D487/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A drug combination containing a TLR7 agonist. Specifically, a drug combination jointly using the compound of formula I acting as a TLR7 agonist and entecavir for the treatment of hepatitis B virus infection and a use thereof, the drug combination having a good anti-hepatitis B virus infection effect.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.